Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity.

ABSTRACT: Background: Cancer remains a leading cause of morbidity and mortality worldwide, and current therapies are limited by toxicity, cost, and resistance. Inhibition of the MDM2-p53 interaction is a promising anticancer strategy, as this pathway is frequently dysregulated across tumors. Spiro-isatin-thiazolidinone derivatives have shown diverse biological activities, including anticancer effects, but require optimization to improve potency and selectivity. The aims were to design, synthesize, and evaluate novel spiro-isatin-thiazolidinone hybrids with enhanced cytotoxicity against cancer cells and reduced toxicity toward normal cells. Methods: Derivatives were designed using molecular docking against MDM2, followed by structural optimization. Cytotoxic activity was evaluated in vi

SUBMITTER: Khylyuk D 

PROVIDER: S-EPMC12567349 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature